மேதாண்த நிறுவனம் ஆஃப் கல்வி News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from மேதாண்த நிறுவனம் ஆஃப் கல்வி. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In மேதாண்த நிறுவனம் ஆஃப் கல்வி Today - Breaking & Trending Today

Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis | Critical Care Medicine | JAMA

Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis | Critical Care Medicine | JAMA
jamanetwork.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from jamanetwork.com Daily Mail and Mail on Sunday newspapers.

France General , United States , Israel General , City Of , United Kingdom , University Of Chicago , Zuid Holland , British Columbia , East Wing , University College , New South Wales , Kuala Lumpur , Comunidad Autonoma De Cataluna , New Jersey , Srinivas Murthy , Panktid Reid , Niklas Broman , Hierro Majadahonda , Julian Torre Cisneros , Francesca Spiga , Julianpt Higgins , Reuven Pizov , Salud Carlos , Olivier Hermine , Natalie Staplin , Janetv Diaz ,

Rheumatoid arthritis drug improves outcomes in severely ill COVID-19 patients, finds new trial

Tocilizumab cuts mortality risk in severely ill COVID-19 patients finds new trial conducted in India


Date Time
Tocilizumab cuts mortality risk in severely ill COVID-19 patients finds new trial conducted in India
Tocilizumab, an anti-inflammatory drug used to treat rheumatoid arthritis, improves outcomes in severely ill COVID-19 patients, finds the results of a new trial conducted in hospitals across India – one of the world’s most ethnically diverse countries.
Researchers from the University of Bristol and Medanta Institute of Education and Research in India who led the study, published in The Lancet Respiratory Medicine, say it adds to existing evidence supporting the drug’s use in critically ill patients.
Conducted in 12 public and private hospitals across India, the COVID India Tocilizumab (COVINTOC) phase 3 randomised controlled trial aimed to investigate whether tocilizumab could prevent disease progression and mortality in hospitalised patients with moderate to severe COVID-19. ....

City Of , United Kingdom , United States , Arvinder Soin , Arvinders Soin , University Of Bristol Medical School , Medanta Institute Of Education , Medanta Liver Transplantation Institute At Gurugram , University Of Bristol , Medanta Institute , Lancet Respiratory Medicine , Medical School , Consultant Paediatric Rheumatologist , Bristol Royal Hospital , Medanta Liver Transplantation Institute , North America , Roche India , Cipla India , Lancet Respiratory , Rheumatoid Arthritis , Anti Inflammatory , Liver Transplant , Clinical Trials , Critically Ill , நகரம் ஆஃப் , ஒன்றுபட்டது கிஂக்டம் ,

Tocilizumab cuts mortality risk in severely ill COVID-19 patients finds new trial conducted in India